Tirzepatide-Induced Injection Site Reaction
Cureus · 13.09.2023
DOI: 10.7759/cureus.45181 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 13.09.2023. Verfasst von Junki Mizumoto. Beteiligte Einrichtung: Department of Medical Education Studies, International Research Center for Medical Education, Graduate School of Medicine, The University of Tokyo, T…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
A male in his 70s developed a rash on his lower abdomen after changing his subcutaneous injection drug from dulaglutide to tirzepatide. The rash diminished after stopping tirzepatide injection. This case illustrated that tirzepatide can potentially lead to an injection site rash, despite another glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being used without adverse reactions. Injection site reactions are one of the potential adverse events associated with GLP-1 RA use. To the best of our knowledge, this is the first reported case of tirzepatide-induced injection site reaction.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Education Studies, International Research Center for Medical Education, Graduate School of Medicine, The University of Tokyo, Tokyo, JPN.
Zitieren
APA
Mizumoto, J. (2023). Tirzepatide-Induced Injection Site Reaction. Cureus. https://doi.org/10.7759/cureus.45181
Vancouver
Mizumoto J. Tirzepatide-Induced Injection Site Reaction. Cureus. 2023. doi:10.7759/cureus.45181
BibTeX
@article{Mizumoto2023,
author = {Mizumoto, Junki},
title = {Tirzepatide-Induced Injection Site Reaction},
journal = {Cureus},
year = {2023},
doi = {10.7759/cureus.45181}
}
EUVIMED